Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4701 - Cabozantinib in metastatic renal cell carcinoma (mRCC): data from UK expanded access program (EAP)


22 Oct 2018


Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care


Tumour Site

Renal Cell Cancer


Alfonso Gomez de Liano Lista


Annals of Oncology (2018) 29 (suppl_8): viii303-viii331. 10.1093/annonc/mdy283


A. Gomez de Liano Lista1, B. Venugopal2, K. Fife3, S. Symeonides4, N.S. Vasudev5, S.M. Rudman6, S. Vohra2, L. Khasati3, C. Pettinger4, B. Szabados1, L. Morrison7, T. Powles8, E. Boleti7

Author affiliations

  • 1 Medical Oncology, Barts Cancer Institute, EC1M 6BQ - London/GB
  • 2 Medical Oncology, Beatson West of Scotland Cancer Centre, G12 0YN - Glasgow/GB
  • 3 Medical Oncology, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, CB2 0QQ - Cambridge/GB
  • 4 Medical Oncology, Cancer Research UK Edinburgh Centre, Edinburgh/GB
  • 5 Oncology, St. James's University Hospital Leeds, LS9 7TF - Leeds/GB
  • 6 Medical Oncology, Guy's and St. Thomas' Hospital NHS Trust, SE1 9RT - London/GB
  • 7 Academic Oncology, Royal Free Hospital School of Medicine, NW3 2QG - London/GB
  • 8 N/a, Barts Cancer Institute, EC1M 6BQ - London/GB


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4701


Cabozantinib demonstrated increased efficacy over everolimus in patients with mRCC progressing on VEGF targeted therapy in the randomised phase III METEOR trial. We report real world experience with Cabozantinib in 7 centres across the UK.


In this retrospective study, patients who started Cabozantinib from September 2016 to September 2017 within the UK EAP were included. Patients had mRCC progressing after at least 1 prior systemic treatment, PS 0-2 and adequate organ function. The goal was to analyse toxicities, efficacy and access to other drugs after progression. Adverse events (AEs) were graded using the NCI CTCAE v.4.0.3. Survival times were calculated from the start of Cabozantinib using a Kaplan-Meier model. Radiological response was assessed locally by RECIST 1.1.


128 patients were included. Median follow-up was 10.5 months. Median age was 62 years, 84% had clear cell histology, and 49% were classified as intermediate risk by IMDC score. 87% had visceral M1 and 52% bone M1. Patients received a median of 2 previous lines (1-6) of therapy. Cabozantinib was used as 2nd line, 3rd line and 4th line or beyond in 56 (44%), 38 (30%) and 34 (26%) patients respectively. Baseline characteristics are summarized in the table. 48 (37%) of the patients developed G3/4 AEs, mainly fatigue (N = 14, 11%), diarrhoea (N = 12, 9%), mucositis (N = 7, 5%) and hand-foot syndrome (N = 6, 5%). No treatment-related deaths were seen. 71 patients (55%) required dose reductions. 12 (15%) discontinued Cabozantinib due to toxicity. Median OS was 9.1 months (95% CI 6.6-11.6), being 14.3 vs 9.3 vs 6.0 months for good, intermediate and poor prognostic patients, respectively (p 0.01). Median PFS was 7.7 months (95% CI 5.3-10.1). Partial response to Cabozantinib was 26%, stable disease 24%, Progressive disease 30% and was not evaluated in 20%. Only 21/81 patients (26%) stopping Cabozantinib started on subsequent treatment.Table: 893P

Baseline characteristicNumber (%)
GenderMale Female87 (68) 41 (32)
AgeMedian (range)62 (11-83)
PS ECOG0 1 220 (16) 85 (66) 23 (18)
HistologyClear Cell Papillary Other107 (84) 13 (10) 8 (6)
IMDC Risc CategoryGood Intermediate Poor Unknown35 (27) 62 (49) 27 (21) 4 (3)
NephrectomyYes No93 (73) 35 (27)
Number of metastatic sites1 2 ≥317 (13) 46 (36) 64 (50)
Metastatic sitesLung Lymph node Bone Liver Brain Pleura/Peritoneal Other92 (72) 55 (43) 66 (52) 42 (33) 14 (11) 19 (15) 47 (37)
Visceral and bone M1 spreadAll patients with visceral M1 Both Visceral + bone M1 Visceral M1 without bone M1110 (87) 55 (43) 54 (42)
Previous lines of therapy1 2 ≥356 (44) 38 (30) 34 (26)
Duration of 1st VEGFR TKI≤6 months >6 months34 (27) 94 (73)
1st subsequent treatment (N = 21)Nivolumab Axitinib Everolimus Others15 (71) 3 (14) 1 (5) 2 (10)
PD-1/PDL1 inhibitors prior to CaboNivolumab PD1/PDL1-VEGF combo27 (21) 10 (8)


Cabozantinib was safe and active in pretreated patients with mRCC.

Clinical trial identification

Legal entity responsible for the study

Alfonso Gomez de Liano.


Has not received any funding.

Editorial Acknowledgement


S. Symeonides: Research funding: Merck Sharp & Dohme. T. Powles: Advisory role and research funding: Roche, AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.